secwatch.observer — SEC 8-K summary
======================================

Issuer:     KYNTRA BIO, INC. (KYNB)
CIK:        0000921299
Form:       8-K
Filed at:   2026-03-16T23:59:59+00:00
Accession:  0001193125-26-108324
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kyntra Bio reports FY2025 revenue $6.4M, net loss $58.2M; cash $109.4M into 2028
--------------------------------------------------------------------------------

- Full yr 2025 revenue from cont ops $6.4M (vs $29.6M in 2024); net loss $58.2M (vs $153.1M).
- Cash, equivalents, investments, and receivables $109.4M as of Dec 31, 2025; runway into 2028.
- Phase 2 monotherapy trial of FG-3246 in mCRPC enrolling; interim analysis expected 2H 2026.
- Phase 3 protocol for roxadustat in LR-MDS anemia submitted to FDA; start targeted 2H 2026.
- Combo trial of FG-3246 + enzalutamide showed median rPFS 7.0 months; data at ASCO GU 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921299/000119312526108324/0001193125-26-108324-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921299/000119312526108324/kynb-20260316.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-108324

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer